Member Info for Timster

Are for relaxing, chilling out after the data from science day has shown there is very little to be concerned about how the pre|CISION platform is performing.

Blimey, yep, desperate times

Tomwinnifilth sending in the big guns

Apologies now I've zoomed in I see the point.

Good to have some true balance on the board at last!

Can you tell us why it's a massive sell for you? I think if you have a quick read of the board and maybe a look at the science day presentation and slides here https://avacta.com/therapeutics-science-day-recording-and-presentations/

You'll see why the majority of LTH on this board don't agree.

0.5% BITL

Why are you so angry richar, you had a spell a few weeks ago where you were quite upbeat and almost jovial?

Next thing you'll be saying you can predict the future with your magic crayons and upside down tea cup handle bar moustache's

Price manipulation at it's finest

Oh yes I check here this morning and it still showed, now gone
https://shorttracker.co.uk/company/GB00BYYW9G87/

Really?

Great news Hurstbot

Wynbore's portfolio

What did you think of the content tiger?

With size buyers arriving from NY any minute you wouldn't want to be out over the weekend.

Exciting times...

Because they don't have a miracle story yet as they aren't targeting what will be targeted in the real world.

Come phase 1b when they target STS that miracle tumour shrinkage story may become a reality.

Welcome back by the way pigster, where you been?

Spot on pigster that's what was said in the presentation

Unless this was that notification in the cohort 4 RNS:
19 patients with a range of advanced and/or metastatic solid tumours enrolled across four cohorts, have been administered AVA6000 to date. On the basis of the very favourable safety profile of AVA6000 in the study to date, the Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies. The Company expects that it will complete these additional cohorts during the first half of 2023.

They've informed us about all the other escalations.

It would be very strange if they chose not to RNS the next ones too.